Search
Regeneron Pharmaceuticals Inc
REGNAdd to Watchlist
651.870USD
+0.690+0.11%
Close 07-23 16:00（ET）Quotes delayed by 15 min
68.45BMarket Cap
15.34P/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-23The current earnings forecast score of Regeneron Pharmaceuticals Inc is 7.81, ranking 92 out of 155 in the Pharmaceuticals industry. The average price target is 767.00, with a high of 1057.00 and a low of 627.00.
Analyst Rating
Based on
31
analysts
Buy
Current Rating
816.016
Target Price
+20.86%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Regeneron Pharmaceuticals Inc
REGN
31
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Regeneron Pharmaceuticals Inc's expected revenue for the next quarter?
Regeneron Pharmaceuticals Inc's expected revenue is 3.82B.
What is Regeneron Pharmaceuticals Inc's price target?
Analysts forecast that Regeneron Pharmaceuticals Inc's price target is USD 767.00, with the highest forecast at USD 1.06K and the lowest forecast at USD 627.00.
How have Regeneron Pharmaceuticals IncREGN's recent earnings per share performed?
The market expectation was USD 6.99, while Regeneron Pharmaceuticals IncREGN's earnings per share (EPS) for the previous quarter was USD 8.19. EPS for the next quarter is expected at USD 10.32.
What is the analyst rating for Regeneron Pharmaceuticals Inc?
Based on the ratings of Regeneron Pharmaceuticals Inc's stock from 31 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.